Definium Therapeutics (DFTX) Inventory Average (2020 - 2021)
Definium Therapeutics (DFTX) reported Inventory Average of $6.4 million for Q2 2021, up 312.6% year-over-year from $1.6 million in Q2 2020, and up 40.34% on a QoQ basis from $4.6 million in Q1 2021.
Definium Therapeutics (DFTX) has 2 years of Inventory Average data on file, last reported at $6.4 million in Q2 2021.
- Quarterly Inventory Average rose 312.6% year-over-year to $6.4 million in Q2 2021, while the trailing twelve-month figure through Jun 2021 was $6.4 million (up 312.6% YoY) and the FY2020 annual result came in at $3.0 million, changed N/A from the prior year.
- Inventory Average climbed to $6.4 million in Q2 2021 per DFTX's latest filing, from $4.6 million in the prior quarter.
- Across five years, Inventory Average topped out at $6.4 million in Q2 2021 and bottomed at $1.6 million in Q2 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inventory Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 30.59 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.73 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 3.15 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 83.37 Mn |
| 10 | Definium Therapeutics | 2.42 Bn | 2.06 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 6.40 Mn |
| Mar 31, 2021 | 4.56 Mn |
| Dec 31, 2020 | 2.28 Mn |
| Sep 30, 2020 | 1.57 Mn |
| Jun 30, 2020 | 1.55 Mn |
| Mar 31, 2020 | 2.33 Mn |